Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue

AIDS

Volumn 23, Issue 12, 2009, Pages 1485-1494

  Murakami, Toshio ^a   Eda, Yasuyuki ^a   Nakasone, Tadashi ^b   Ami, Yasushi ^b   Someya, Kenji ^b   Yoshino, Naoto ^b   Kaizu, Masahiko ^b   Izumi, Yasuyuki ^b   Matsui, Hajime ^a   Shinohara, Katsuaki ^b   Yamamoto, Naoki ^b   Honda, Mitsuo ^b  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Anti V3 mAb; CD4+ T cells; HIV 1; KD 247; Lymphoid tissue; Passive immunization; Simian human immunodeficiency virus

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KD 247; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; MALE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD;

ANIMALS; ANTIBODIES, MONOCLONAL; ATROPHY; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV ENVELOPE PROTEIN GP120; IMMUNIZATION, PASSIVE; LYMPHOID TISSUE; MACACA FASCICULARIS; PEPTIDE FRAGMENTS; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; THYMUS GLAND; VIRAL LOAD;

EID: 68649084966     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e5331     Document Type: Article

References (48)

1. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006; 124:677-681.
2. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24: 227-255.
3. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006; 5:579-595.
4. Lin G, Nara PL. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res 2007; 5:514-541.
5. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355:728-730.
6. Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K, Yone-mura H, et al. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 2006; 80: 5552-5562.
7. Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol 2006; 80:5563-5570.
8. Matsushita S, Takahama S, Shibata J, Kimura T, Shiosaki K, Eda Y, et al. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247. Hum Antibodies 2005; 14:81-88.
9. Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, Voss G, et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004; 78:5983-5995.
10. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 2003; 100:15131-15136.
11. Ferrantelli F, Buckley KA, Rasmussen RA, Chalmers A, Wang T, Li P-L, et al. Time dependence of protective postexposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 2007; 358:69-78.
12. Ruprecht RM, Ferrantelli F, Kitabwalla M, Xu W, McClure HM. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003; 21:3370-3373.
13. Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, Van Rompay K, et al., Ghent IAS Working Group on HIV in Women and Children. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35:169-177.
14. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al., International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-843.
15. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
16. Shinohara K, Sakai K, Ando S, Ami Y, Yoshino N, Takahashi E, et al. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol 1999; 80:1231-1240.
17. + T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus. Clin Exp Immunol 2000; 122:381-389.
18. Kaizu M, Sato H, Ami Y, Izumi Y, Nakasone T, Tomita Y, et al. Infection of macaques with an R5-tropic SHIV bearing a chimeric envelope carrying subtype E V3 loop among subtype B framework. Arch Virol 2003; 148:973-988.
19. Yoshino N, Ami Y, Terao K, Tashiro F, Honda M. Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using antihuman cross-reactive antibodies. Exp Anim 2000; 49:97-110.
20. Okamoto Y, Eda Y, Ogura A, Shibata S, Amagai T, Katsura Y, et al. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate. J Immunol 1998; 160:69-76.
21. Matsushita S, Maeda H, Kimachi K, Eda Y, Maeda Y, Murakami T, et al. Characterization of a mouse/human chimeric monoclonal antibody (Cβ1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. AIDS Res Hum Retroviruses 1992; 8:1107-1115.
22. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al., and the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
23. Wood GS. The immunohistology of lymph nodes in HIV infection: a review. Prog AIDS Pathol 1990; 2:25-32.
24. Cloyd MW, Chen JJY, Adeqboyega P, Wang L. How does HIV cause depletion of CD4 lymphocytes? A mechanism involving virus signaling through its cellular receptors. Curr Mol Med 2001; 1:545-550.
25. Motohara M, Ibuki K, Miyake A, Fukazawa Y, Inaba K, Suzuki H, et al. Impaired T-cell differentiation in the thymus at the early stages of acute pathogenic chimeric simian-human immunodeficiency virus (SHIV) infection in contrast to less pathogenic SHIV infection. Microbes Infect 2006; 8:1539-1549.
26. Margolin DH, Saunders EH, Bronfin B, de Rosa N, Axthelm MK, Goloubeva OG, et al. Germinal center function in the spleen during simian HIV infection in rhesus monkeys. J Immunol 2006; 177:1108-1119.
27. Zhang Z-Q, Casimiro DR, Schleif WA, Chen M, Citron M, Davies M-E, et al. Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology 2007; 361:455-464.
28. Yoshino N, Ryu T, Sugamata M, lhara T, Ami Y, Shinohara K, et al. Direct detection of apoptotic cells in peripheral blood from highly pathogenic SHIV-inoculated monkey. Biochem Biophys Res Commun 2000; 268:868-874.
29. DH12R is systemic and synchronous. J Virol 2002; 76:379-391.
30. Gratton S, Cheynier R, Dumaurier M-J, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A 2000; 97:14566- 14571.
31. de Paiva GR, Laurent C, Godel A, da Silva NA Jr, March M, Delsol G, et al. Discovery of human immunodeficiency virus infection by immunohistochemistry on lymph node biopsies from patients with unexplained follicular hyperplasia. Am J Surg Pathol 2007; 31:1534-1538.
32. Zamarchi R, Barelli A, Borri A, Petralia G, Ometto L, Masiero S, et al. B cell activation in peripheral blood and lymph nodes during HIV infection. AIDS 2002; 16:1217-1226.
33. + T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008; 111:699-704.
34. Biancotto A, Grivel J-C, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109:4272-4279.
35. Nokta MA, Li X-D, Nichols J, Pou A, Asmuth D, Pollard RB. Homeostasis of naive and memory T cell subpopulations in peripheral blood and lymphoid tissues in the context of human immunodeficiency virus infection. J Infect Dis 2001; 183:1336-1342.
36. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533.
37. Taruishi M, Terashima K, Dewan Z, Dewan MZ, Yamamoto N, I keda S, et al. Role of follicular dendritic cells in the early HIV-1 infection: in vitro model without specific antibody. Microbiol Immunol 2004; 48:693-702.
38. Turville SG, Aravantinou M, Stössel H, Romani N, Robbiani M. Resolution of de novo HIV production and trafficking in immature dendritic cells. Nat Methods 2008; 5:75-85.
39. Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol 2005; 79:2042-2049.
40. Wilflingseder D, Banki Z, Garcia E, Pruenster M, Pfister G, Muellauer B, et al. IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells. J Immunol 2007; 178:7840-7848.
41. Foresman L, Jia F, Li Z, Wang C, Stephans EB, Sahni M, et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses 1998; 14:1035-1043.
42. + individuals migrate rapidly to lymph nodes and bone marrow: support for homing theory of CD4 cell depletion. J Leukoc Biol 2002; 72:271-278.
43. + T cells and circulating in plasma. J Virol 2002; 76:8855-8863.
44. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995; 377:740-744.
45. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-39.
46. Mascola JR. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002; 20:1922-1925.
47. Bansal GP. A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006. Biologicals 2007; 35:367-371.
48. Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, et al. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (mAhs) against human immunodeficiency virus type 1 envelope gp120 (mAb 2G12) and gp41 (mAbs 4E10 and 2F5). Antimicrob Agents Chemother 2006; 50:1773-1779.